Prostate specific membrane antigen mRNA in blood as a potential predictor of biochemical recurrence after radical prostatectomy.
We investigated whether the detection of prostate specific membrane antigen (PSMA) in blood preoperatively has predictive value for biochemical recurrence (BCR) after radical prostatectomy in patients with prostate cancer. All 134 patients scheduled to receive radical prostatectomy for prostate cancer were prospectively enrolled. The authors used nested reverse transcriptase-polymerase chain reaction (RT-PCR) assay to detect PSMA mRNA-bearing cells in peripheral blood, and analyzed the ability of PSMA mRNA positivity to predict BCR after surgery. PSMA-mRNA was detected in 24 (17.9%) patients by RT-PCR. Over a median follow-up of 20 months (range, 3 to 46 months), BCR developed in 15 patients (11.2%) and median time to BCR was 7 months (range, 3 to 25 months). Kaplan-Meier analysis revealed a significant difference between those positive or negative for PSMA in terms of recurrence-free actuarial probability (log rank P=0.0039). Multivariate analysis showed that positivity for PSMA mRNA (HR: 3.697, 95% CI 1.285-10.634, P=0.015) and a biopsy Gleason score of >or=7 (HR: 4.500, 95% CI 1.419-14.274, P=0.011) were independent preoperative predictors of BCR. The presence of PSMA mRNA in peripheral blood can be used to predict BCR after radical prostatectomy.
Joung
Jae Young
JY
Center for Prostate Cancer, Goyang, Korea.
Cho
Kang Su
KS
Chung
Han Soo
HS
Cho
In-Chang
IC
Kim
Jung Eun
JE
Seo
Ho Kyung
HK
Chung
Jinsoo
J
Park
Weon Seo
WS
Choi
Moon Kyung
MK
Lee
Kang Hyun
KH
D000368:Aged; D000954:Antigens, Surface / Q000097:blood* / Q000235:genetics; D043425:Glutamate Carboxypeptidase II / Q000097:blood* / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis*; D011237:Predictive Value of Tests; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000601:surgery; D012333:RNA, Messenger / Q000097:blood*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012720:Severity of Illness Index; D013997:Time Factors
D000954:Antigens, Surface; D012333:RNA, Messenger; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II
Urology. 1996 Aug;48(2):326-34
8753752
Cancer Res. 1997 Jun 15;57(12):2321-4
9192800
Br J Urol. 1996 Mar;77(3):411-7
8814848
Ann N Y Acad Sci. 2000 Apr;906:110-23
10818606
JAMA. 2003 May 28;289(20):2695-700
12771116
Semin Surg Oncol. 2000 Jan-Feb;18(1):17-28
10617893
J Urol. 2001 Mar;165(3):851-6
11176485
Int J Urol. 2007 Jul;14(7):635-43
17645609
Urol Clin North Am. 1997 May;24(2):367-78
9126234
J Urol. 2006 Sep;176(3):991-5
16890678
Urology. 1994 Jun;43(6):765-75
7515202
Cancer Res. 1998 Apr 1;58(7):1456-9
9537248
J Urol. 2000 Jun;163(6):2022-9
10799250
Clin Cancer Res. 1997 Jul;3(7):1215-20
9815802
Int J Cancer. 1999 Aug 20;84(4):360-4
10404086
Cancer Res. 1993 Jan 15;53(2):227-30
8417812
BJU Int. 1999 Jul;84(1):112-7
10444137
Int J Cancer. 1995 Sep 4;62(5):552-8
7665226
Clin Chem. 1995 Dec;41(12 Pt 1):1698-704
7497608
J Urol. 1996 Nov;156(5):1560-6
8863538
Cancer Res. 1994 Dec 15;54(24):6306-10
7527294
Cancer Res. 1992 Nov 1;52(21):6110-2
1382851